Vernalis PLC Regulatory News (VER)

4 Jun 2007 15:08

Vernalis PLC04 June 2007 4th June 2007 Vernalis plc Director's Share Dealing WINNERSH, U.K 4th June 2007 -- Vernalis plc (LSE: VER) ("Vernalis" or the"Company") announces that it was informed today that George Kennedy,Non-Executive Director of the Company, today bought 30,000 Ordinary Shares of 5pence each at a price of 61.75 pence per share. Following this purchase of shares, Mr Kennedy is the beneficial owner of 79,094Ordinary Shares, representing 0.025% of the Company's current issued sharecapital. - Ends - Enquiries:Vernalis plc +44 (0) 118 977 3133Simon Sturge, Chief Executive OfficerTony Weir, Chief Financial Officer Brunswick Group +44 (0) 20 7404 5959Jon ColesJustine McIlroy Lazar Partners LtdGregory Gin 212-867-1762 Notes to Editors About Vernalis Vernalis is a speciality bio-pharmaceutical company focused on products marketedto specialist neurologists. The company has two marketed products, Frova(R) andApokyn(R), and a development pipeline focused on neurology and central nervoussystem disorders. The company has eight products in clinical development andcollaborations with leading, global pharmaceutical companies including Novartis,Biogen Idec and Serono. Vernalis has established a US commercial operation topromote Apokyn(R) and co-promote Frova(R) alongside its North American licensingpartner, Endo Pharmaceuticals, progressing the company towards its goal ofbecoming a sustainable, self-funding, R&D-driven, speciality bio-pharmaceuticalcompany. For further information about Vernalis, please visit: www.vernalis.com Product Indication Phase Phase Phase Registration Market Marketing Rights I II III Apokyn(R) Parkinson's Disease x North America Frova(R) Migraine x US milestones & royalties - Endo (EU - royalties) Frova(R) Menstrual x US milestones & Migraine royalties - Endo Prevention (EU - royalties) V1512 Parkinson's x World Wide Disease (excl. Italy) V10153 Ischaemic x World Wide stroke V1003 Acute Pain x US Profit share Option Reckitt Benckiser V3381 Neuropathic x World Wide Pain V2006 Parkinson's x US Co-promotion Disease Biogen Idec MMPI Multiple x None - royalty Sclerosis (Serono) V24343 Obesity x World Wide Vernalis Forward-Looking Statement This news release may contain forward-looking statements that reflect theCompany's current expectations regarding future events including the clinicaldevelopment and regulatory clearance of the Company's products, the Company'sability to find partners for the development and commercialisation of itsproducts, as well as the Company's future capital raising activities.Forward-looking statements involve risks and uncertainties. Actual events coulddiffer materially from those projected herein and depend on a number of factorsincluding the success of the Company's research strategies, the applicability ofthe discoveries made therein, the successful and timely completion of clinicalstudies, the uncertainties related to the regulatory process, the ability of theCompany to identify and agree beneficial terms with suitable partners for thecommercialisation and/or development of its products, as well as the achievementof expected synergies from such transactions, the acceptance of Frova(R) andApokyn(R) and other products by consumers and medical professionals, thesuccessful integration of completed mergers and acquisitions and achievement ofexpected synergies from such transactions, and the ability of the Company toidentify and consummate suitable strategic and business combinationtransactions. This information is provided by RNS The company news service from the London Stock Exchange